
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZNF346 (zinc finger protein 346) encodes a nucleolar zinc finger protein that preferentially binds double-stranded RNA and RNA/DNA hybrids. Its zinc finger domains contribute to RNA binding and nucleolar localization, supporting a role in RNA-associated cellular processes. ZNF346 may also influence cell growth and survival and has been reported to protect neurons from inappropriate cell-cycle re-entry by promoting expression of the cell-cycle inhibitor p21.
5637 is a human bladder carcinoma cell line established from a primary bladder tumor of a 68-year-old male patient. The cells are known to produce multiple growth factors, including stem cell factor (SCF), interleukins, and colony-stimulating factors. 5637 cells are used as a model for studying bladder cancer biology, tumor-associated signaling, and growth factor regulation.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?